Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Withdrawal: Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo : Role of mitochondrial reactive nitrogen species.

Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH.

J Biol Chem. 2019 Sep 6;294(36):13525. doi: 10.1074/jbc.W119.010595. No abstract available.

2.

Vibrio parahaemolyticus in the Chesapeake Bay: Operational In Situ Prediction and Forecast Models Can Benefit from Inclusion of Lagged Water Quality Measurements.

Davis BJK, Jacobs JM, Zaitchik B, DePaola A, Curriero FC.

Appl Environ Microbiol. 2019 Aug 14;85(17). pii: e01007-19. doi: 10.1128/AEM.01007-19. Print 2019 Sep 1.

3.

Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP.

Radiother Oncol. 2019 Jun 6;140:68-75. doi: 10.1016/j.radonc.2019.05.016. [Epub ahead of print]

PMID:
31177044
4.

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.

Mason BR, Eastham JA, Davis BJ, Mynderse LA, Pugh TJ, Lee RJ, Ippolito JE.

J Natl Compr Canc Netw. 2019 May 1;17(5):506-513. doi: 10.6004/jnccn.2019.7306.

PMID:
31085758
5.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
6.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

7.

Speech production and disorganization in schizotypy: Investigating the role of cognitive and affective systems.

Marggraf MP, Davis BJ, Hardin KL, Abplanalp SJ, Haller JA, DeCrescenzo P, Minor KS.

J Psychiatr Res. 2019 Jul;114:11-16. doi: 10.1016/j.jpsychires.2019.03.023. Epub 2019 Mar 24.

PMID:
30991167
8.

The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration.

Wallner PE, Kachnic LA, Alektiar KM, Davis BJ, Hardenbergh PH, Ng AK.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):21-23. doi: 10.1016/j.ijrobp.2019.01.090. No abstract available.

PMID:
30967226
9.

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e536-e540. doi: 10.1016/j.clgc.2019.01.019. Epub 2019 Feb 6. No abstract available.

PMID:
30902522
10.

Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds.

Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR.

Brachytherapy. 2019 May - Jun;18(3):306-312. doi: 10.1016/j.brachy.2019.01.007. Epub 2019 Mar 8.

PMID:
30853392
11.

A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.

Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK.

Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4.

PMID:
30718919
12.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

13.

Performance of Cold Chains for Chesapeake Bay Farmed Oysters and Modeled Growth of Vibrio parahaemolyticus.

Love DC, Lane RM, Davis BJK, Clancy K, Fry JP, Harding J, Hudson B.

J Food Prot. 2019 Jan;82(1):168-178. doi: 10.4315/0362-028X.JFP-18-044.

PMID:
30702938
14.

Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures.

Erlanson DA, Davis BJ, Jahnke W.

Cell Chem Biol. 2019 Jan 17;26(1):9-15. doi: 10.1016/j.chembiol.2018.10.001. Epub 2018 Oct 25. Review.

PMID:
30482678
15.

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.

Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ.

Brachytherapy. 2019 Jan - Feb;18(1):1-7. doi: 10.1016/j.brachy.2018.09.003. Epub 2018 Oct 4.

PMID:
30293836
16.

Quantification of Blood Velocity with 4D Digital Subtraction Angiography Using the Shifted Least-Squares Method.

Wu Y, Shaughnessy G, Hoffman CA, Oberstar EL, Schafer S, Schubert T, Ruedinger KL, Davis BJ, Mistretta CA, Strother CM, Speidel MA.

AJNR Am J Neuroradiol. 2018 Oct;39(10):1871-1877. doi: 10.3174/ajnr.A5793. Epub 2018 Sep 13.

17.

The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.

Chang AJ, McBride S, Keyes M, Chung HT, Davis BJ, Cox BW, Crook J, Demanes DJ, Hsu IC, Kamrava M, Krauss DJ, Morton G, Orio Iii PF, Roach Iii M, Venkat PS, Vigneault E, Zelefsky MJ.

J Clin Oncol. 2018 Sep 13:JCO1800626. doi: 10.1200/JCO.18.00626. [Epub ahead of print] No abstract available.

PMID:
30212298
18.

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.

Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240. doi: 10.1016/j.ijrobp.2018.09.001. Epub 2018 Sep 8.

PMID:
30205124
19.

α1L-adrenoceptors mediate contraction of human erectile tissue.

Davis BJ, Chapple CR, Sellers DJ, Naylor AL, Sillar D, Campbell A, Chess-Williams R.

J Pharmacol Sci. 2018 Aug;137(4):366-371. doi: 10.1016/j.jphs.2018.08.003. Epub 2018 Aug 9.

20.

Low dose rate prostate brachytherapy.

Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R.

Transl Androl Urol. 2018 Jun;7(3):341-356. doi: 10.21037/tau.2017.12.15. Review.

21.

Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.

Lieng H, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Shakespeare TP, Sidhom M, Skala M, Wiltshire K, Yaxley J, Kneebone A.

Radiother Oncol. 2018 Nov;129(2):377-386. doi: 10.1016/j.radonc.2018.06.027. Epub 2018 Jul 20. Review.

PMID:
30037499
22.

ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer.

Expert Panel on Urologic Imaging:, Froemming AT, Verma S, Eberhardt SC, Oto A, Alexander LF, Allen BC, Coakley FV, Davis BJ, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Wang CL, Remer EM.

J Am Coll Radiol. 2018 May;15(5S):S132-S149. doi: 10.1016/j.jacr.2018.03.019.

PMID:
29724417
23.

The role of signals in two variations of differential-reinforcement-of-low-rate procedures.

Becraft JL, Borrero JC, Davis BJ, Mendres-Smith AE, Castillo MI.

J Appl Behav Anal. 2018 Jan;51(1):3-24. doi: 10.1002/jaba.431. Epub 2018 Jan 3.

PMID:
29313972
24.

Words matter: Implementing the electronically activated recorder in schizotypy.

Minor KS, Davis BJ, Marggraf MP, Luther L, Robbins ML.

Personal Disord. 2018 Mar;9(2):133-143. doi: 10.1037/per0000266. Epub 2017 Dec 7.

PMID:
29215902
25.

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2017 Mar 20;2(3):437-454. doi: 10.1016/j.adro.2017.03.003. eCollection 2017 Jul-Sep. Review.

26.

Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39. doi: 10.1016/j.prro.2017.07.011. Epub 2017 Jul 20. Review.

27.

Semantic coherence in psychometric schizotypy: An investigation using Latent Semantic Analysis.

Marggraf MP, Cohen AS, Davis BJ, DeCrescenzo P, Bair N, Minor KS.

Psychiatry Res. 2018 Jan;259:63-67. doi: 10.1016/j.psychres.2017.09.078. Epub 2017 Sep 30.

PMID:
29028526
28.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
29.

Environmental Determinants of Vibrio parahaemolyticus in the Chesapeake Bay.

Davis BJK, Jacobs JM, Davis MF, Schwab KJ, DePaola A, Curriero FC.

Appl Environ Microbiol. 2017 Oct 17;83(21). pii: e01147-17. doi: 10.1128/AEM.01147-17. Print 2017 Nov 1.

30.

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Expert Panel on Radiation Oncology-Prostate:, Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2016 Oct 20;2(1):62-84. doi: 10.1016/j.adro.2016.10.002. eCollection 2017 Jan-Mar. Review. No abstract available.

31.

Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.

Schnakenberg Martin AM, Bonfils KA, Davis BJ, Smith EA, Schuder K, Lysaker PH.

Schizophr Res Cogn. 2016 Oct 10;6:15-21. doi: 10.1016/j.scog.2016.09.001. eCollection 2016 Dec.

32.

The evolution of brachytherapy for prostate cancer.

Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM.

Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Review.

PMID:
28664931
33.

Sternum First, Perhaps Pelvis Later.

Davis BJ, Park SS.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):496. doi: 10.1016/j.ijrobp.2017.04.020. No abstract available.

PMID:
28581389
34.

Brachytherapy in the Management of Prostate Cancer.

Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R.

Surg Oncol Clin N Am. 2017 Jul;26(3):491-513. doi: 10.1016/j.soc.2017.01.008. Epub 2017 May 11. Review.

PMID:
28576185
35.

Renal Mass and Localized Renal Cancer: AUA Guideline.

Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, Clark PE, Davis BJ, Derweesh IH, Giambarresi L, Gervais DA, Hu SL, Lane BR, Leibovich BC, Pierorazio PM.

J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.

PMID:
28479239
36.

ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Expert Panel on Urologic Imaging:, Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Verma S, Wang CL, Remer EM, Eberhardt SC.

J Am Coll Radiol. 2017 May;14(5S):S245-S257. doi: 10.1016/j.jacr.2017.02.026. Review.

PMID:
28473080
37.

Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption.

Marcus DJ, Henderson-Redmond AN, Gonek M, Zee ML, Farnsworth JC, Amin RA, Andrews MJ, Davis BJ, Mackie K, Morgan DJ.

PLoS One. 2017 Apr 20;12(4):e0174826. doi: 10.1371/journal.pone.0174826. eCollection 2017.

38.

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.

Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952.

39.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

40.

Feasibility of reduced-dose three-dimensional/four-dimensional-digital subtraction angiogram using a weighted edge preserving filter.

Oberstar EL, Speidel MA, Davis BJ, Strother CM, Mistretta CA.

J Med Imaging (Bellingham). 2017 Jan;4(1):013501. doi: 10.1117/1.JMI.4.1.013501. Epub 2017 Jan 11.

41.

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.

McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ; Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2017 Feb;40(1):1-10. doi: 10.1097/COC.0000000000000354.

PMID:
28059930
42.

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N.

Brachytherapy. 2017 Mar - Apr;16(2):266-276. doi: 10.1016/j.brachy.2016.10.002. Epub 2016 Dec 7.

PMID:
27964905
44.

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.

Jethwa KR, Furutani KM, Mynderse LA, Wilson TM, Choo R, King BF, Bergstralh E, Davis BJ.

J Contemp Brachytherapy. 2016 Oct;8(5):371-378. Epub 2016 Nov 4.

45.

Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED.

Eur Urol. 2017 Mar;71(3):340-348. doi: 10.1016/j.eururo.2016.08.055. Epub 2016 Sep 3.

46.

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N.

Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27.

47.

Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray.

Birckhead BJ, Fossum CC, Deufel CL, Furutani KM, Merrell KW, Schueler BA, Mynderse LA, Choo R, Davis BJ.

Brachytherapy. 2016 Nov - Dec;15(6):714-721. doi: 10.1016/j.brachy.2016.07.004. Epub 2016 Aug 16.

PMID:
27542893
48.

Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil.

Zattoni F, Kawashima A, Morlacco A, Davis BJ, Nehra AK, Mynderse LA, Froemming AT, Jeffrey Karnes R.

Pract Radiat Oncol. 2017 Jan - Feb;7(1):42-49. doi: 10.1016/j.prro.2016.06.003. Epub 2016 Jun 14.

PMID:
27527896
49.

Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic.

Marcus DJ, Zee ML, Davis BJ, Haskins CP, Andrews MJ, Amin R, Henderson-Redmond AN, Mackie K, Czyzyk TA, Morgan DJ.

PLoS One. 2016 Aug 8;11(8):e0160462. doi: 10.1371/journal.pone.0160462. eCollection 2016.

50.

CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.

Law ME, Ferreira RB, Davis BJ, Higgins PJ, Kim JS, Castellano RK, Chen S, Luesch H, Law BK.

Breast Cancer Res. 2016 Aug 5;18(1):80. doi: 10.1186/s13058-016-0741-1.

Supplemental Content

Loading ...
Support Center